FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer

Inclusion Criteria: * Male or female, ≥18 years old; * Patients with histopathologically confirmed unresectable or metastatic colorectal cancer who have not previously received chemotherapy or targeted therapy for unresectable or metastatic lesions; * Have at least one measurable lesion according to RECIST 1.1 standards; * ECOG PS score: 0-2; * Expected survival greater than 3 months; * Routine blood routine, liver and kidney function, electrocardiogram and other routine tests were basically normal, no contraindications of chemotherapy; * The subjects voluntarily joined the study, signed the informed consent, had good compliance, and cooperated with follow-up visits; * Researchers believe treatment can benefit. Exclusion Criteria: * A proven allergy to the test drug and/or its excipients; * Pregnant or lactating women; * Patients judged by the investigator to be unsuitable for inclusion in this study;